

Member Name: \_\_\_\_\_ Member ID: \_\_\_\_\_ Member DOB: \_\_\_\_\_  
Drug Name: \_\_\_\_\_ Strength: \_\_\_\_\_ Directions (including frequency): \_\_\_\_\_  
Physician Name: \_\_\_\_\_ Physician Phone #: \_\_\_\_\_ Specialty: \_\_\_\_\_  
Physician Fax #: \_\_\_\_\_ Pharmacy Name: \_\_\_\_\_ Pharmacy Phone: \_\_\_\_\_

**Horizon NJ Health**  
***Gonadotropin Releasing Hormones agonists and antagonists – Medical Necessity Request***

**\*\*Complete pages 1, 2, and 3 for New/Initial Requests\*\***

**Contraindication Information:**

- Is the member pregnant or planning to become pregnant while on therapy? **Yes or No**
- Is the member breast-feeding? **Yes or No**
- Does the member have Osteoporosis? **Yes or No**
- Does the member have Severe Hepatic impairment? **Yes or No**
- Will the member be receiving strong anion transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine and gemfibrozil) concomitantly? **Yes or No**

**Diagnosis Information** (please indicate diagnosis and answer related questions):

**Prostate Cancer**

- a) Is the disease metastatic (including N1 metastases to lymph nodes and M1 distant metastases)? **Yes or No**
  - b) Is the disease advanced or locally advanced? **Yes or No**
  - c) Is the disease localized? **Yes or No**
    - a. If Yes, will the member be receiving radiation therapy?
      - Yes**
        - i. What is the patient's risk?  Intermediate  High  Very High
        - ii. How will the drug be given in relation to the radiation therapy?  Neoadjuvant  Concomitant  Adjuvant
      - No**
        - i. Please indicate if the member has any of the following (please indicate all that apply):
          - Disease recurrence after radiation therapy or brachytherapy
          - Very high risk disease and is not a candidate for definitive therapy
          - Progressive castration-naïve disease
  - d) Is the request for palliative therapy for men? **Yes or No**
    - a. If Yes, please indicate if the member has any of the following (please indicate all that apply):
      - Life expectancy  $\leq 5$  years
        - a. If yes, please indicate if the member has:
          - High Risk  Very High Risk  Regional  Metastatic Disease
          - Disease progression during observation with symptom development
      - Changes in Prostate-specific antigen (PSA) level suggesting symptom development is likely
- e) Please provide any additional information about the member's disease state:  
\_\_\_\_\_  
\_\_\_\_\_

**Uterine Fibroids (Leiomyomata)**

- a) Does the member have anemia due to the fibroids? **Yes or No**
- b) Will the member be undergoing surgery for the fibroids? **Yes or No**
- c) Has the member previously had surgery for the fibroids? **Yes or No**
- d) Has the member tried iron therapy and if so, for how long? \_\_\_\_\_
- e) Did the member respond to iron therapy? **Yes or No**
  - a. If no, please let us know the specific reason for failure: \_\_\_\_\_
- f) Will the member be receiving iron with the Lupron? **Yes or No**
  - a. If no, please let us know why not? \_\_\_\_\_
- g) What is the size of the fibroid(s)? \_\_\_\_\_

Physician office's signature\* \_\_\_\_\_ Print Name \_\_\_\_\_

\*Form must be completed and signed by physician or licensed representative from the physician's office.

Member Name: \_\_\_\_\_ Member ID: \_\_\_\_\_ Member DOB: \_\_\_\_\_

Drug Name: \_\_\_\_\_ Strength: \_\_\_\_\_ Directions (including frequency): \_\_\_\_\_

Physician Name: \_\_\_\_\_ Physician Phone #: \_\_\_\_\_ Specialty: \_\_\_\_\_

Physician Fax #: \_\_\_\_\_ Pharmacy Name: \_\_\_\_\_ Pharmacy Phone: \_\_\_\_\_

**Precocious Puberty**

- a) Is the precocious puberty either true or central? **Yes or No**
- b) Has tumor been ruled out by appropriate diagnostic procedure? **Yes or No**
- c) Does the member have an onset of secondary sexual characteristics that occurred at or before age 9? **Yes or No**

d) Does the member **only** have pubic hair and/or axillary hair and/or axillary odor as the **only** signs of sexual development? **Yes or No**

i. If Yes, does the member have one of the following (please indicate which):

- Diagnosis of Premature Adrenarche has been excluded
- Had a pubertal response to a GnRH stimulation test
- Bone age advanced one year beyond the chronological age
- Diagnosis has been confirmed by an endocrinologist
- None of the above

**Ovarian Cancer**

- a) Please indicate which applies: Is the member:  Pre-operative  Post-operative
- b) Does the member have any of the following (please indicate all that apply):
  - Grade 1 endometrioid epithelial carcinoma or Low-grade serous carcinoma
    - a) Does the member have Stage IC, Stage II-IV disease? **Yes or No**
  - Borderline epithelial tumors with invasive implants
  - Recurrence of epithelial ovarian/fallopian tube/primary peritoneal disease
    - a) Is the member resistant or intolerant to cytotoxic or targeted therapy or has the member failed preferred cytotoxic or targeted therapy? **Yes or No**
  - Recurrence of malignant sex cord-stromal tumor (i.e. granulosa cell tumor)
  - None of the above

d) Which therapies has the member previously failed, not tolerated, or has a contraindication to?

\_\_\_\_\_

\_\_\_\_\_

**Ovarian Protection during Chemotherapy**

- a) Will the medication be administered while receiving chemotherapy treatment? **Yes or No**
- b) Is the member premenopausal? **Yes or No**

**Breast Cancer**

- a) Is it recurrent? **Yes or No**
- b) Is it metastatic? **Yes or No**
- c) What is the member's menopausal status?  Premenopausal  Perimenopausal  Postmenopausal
- d) Does the member have hormone receptor positive breast cancer? **Yes or No**
- e) What therapies will this medication be given in combination with? \_\_\_\_\_

\_\_\_\_\_

**Dysfunctional (Abnormal) Uterine Bleeding**

- a) Will the member be undergoing surgery (endometrial ablation)? **Yes or No**
- b) What is the abnormal bleeding associated with? (If it is due to one of the listed diagnoses, please also choose that diagnosis and answer related questions). \_\_\_\_\_
- c) How many depot injections will the member receive before surgery (endometrial ablation)? \_\_\_\_\_
- d) Once depot injections are given, after how many weeks will surgery be performed ? \_\_\_\_\_

Physician office's signature\* \_\_\_\_\_ Print Name \_\_\_\_\_

\*Form must be completed and signed by physician or licensed representative from the physician's office.

Member Name: \_\_\_\_\_ Member ID: \_\_\_\_\_ Member DOB: \_\_\_\_\_

Drug Name: \_\_\_\_\_ Strength: \_\_\_\_\_ Directions (including frequency): \_\_\_\_\_

Physician Name: \_\_\_\_\_ Physician Phone #: \_\_\_\_\_ Specialty: \_\_\_\_\_

Physician Fax #: \_\_\_\_\_ Pharmacy Name: \_\_\_\_\_ Pharmacy Phone: \_\_\_\_\_

**Menorrhagia (Heavy bleeding)/ Excessive or frequent menstruation (ICD-9 code 626.2)**

- a) What is the heavy bleeding associated with? (If it is due to one of the listed diagnoses, please also choose that diagnosis and answer related questions). \_\_\_\_\_  
\_\_\_\_\_

**Suppression of Menstruation or Ovarian Protection during Transplant**

- a) Will the member be undergoing Bone Marrow Transplant? **Yes or No**  
b) Is the member premenopausal? **Yes or No**

**Endometriosis**

- a) How many total weeks of therapy has the member previously received of the requested drug? \_\_\_\_\_  
b) Does the member have pain? **Yes or No**  
- If **Yes**, what is the severity of the pain?  Mild  Moderate  Severe  
c) Does the member have Dyspareunia? **Yes or No**  
d) Does the member have moderate hepatic impairment (Child-Pugh Class B)? **Yes or No**

**Gender Identity Disorder/Gender Incongruence or Gender Dysphoria**

**For Adolescent members:**

- a) Is the member 10-19 years of age? **Yes or No**  
b) Has the member undergone surgery for gender reassignment (e.g. gonadectomy)? **Yes or No**  
c) Does the member fulfill the DSM V criteria for gender dysphoria? **Yes or No**  
d) Has the member experienced puberty to at least Tanner stage 2? **Yes or No**  
e) Has the member had (early) pubertal changes that have resulted in an increase of their gender dysphoria? **Yes or No**  
f) Does the member suffer from a psychiatric comorbidity that interferes with the diagnostic work-up or treatment? **Yes or No**  
g) Will the member be psychological and social support during treatment? **Yes or No**  
h) Does the member demonstrate knowledge and understanding of the expected outcomes of GnRH analog treatment?  
**Yes or No**

**For Adult members:**

- a) Is the member 20 years of age or older? **Yes or No**  
b) Is the member receiving gender-affirming hormone therapy (e.g., testosterone, estrogen) together with GnRH **Yes or No**  
c) Has the member undergone surgery for gender reassignment (e.g. gonadectomy)? **Yes or No**  
d) Does the member fulfill the DSM V criteria for gender dysphoria? **Yes or No**  
e) Does the member have the ability to make a fully informed decision and to consent for treatment? **Yes or No**  
f) Are coexistent mental health conditions reasonably well controlled? **Yes or No**

**Other:** \_\_\_\_\_

Physician office's signature\* \_\_\_\_\_ Print Name \_\_\_\_\_

\*Form must be completed and signed by physician or licensed representative from the physician's office.

Member Name: \_\_\_\_\_ Member ID: \_\_\_\_\_ Member DOB: \_\_\_\_\_  
Drug Name: \_\_\_\_\_ Strength: \_\_\_\_\_ Directions (including frequency): \_\_\_\_\_  
Physician Name: \_\_\_\_\_ Physician Phone #: \_\_\_\_\_ Specialty: \_\_\_\_\_  
Physician Fax #: \_\_\_\_\_ Pharmacy Name: \_\_\_\_\_ Pharmacy Phone: \_\_\_\_\_

**\*\*Complete pages 4 and 5 ONLY for subsequent/renewal requests\*\***

**Diagnosis Information** (please indicate diagnosis and answer related questions):

**Prostate Cancer**

- a) Is the disease metastatic (including N1 metastases to lymph nodes and M1 distant metastases)? **Yes or No**
- b) Is the disease advanced or locally advanced? **Yes or No**
- c) Is the disease localized? **Yes or No**
  - a. If Yes, will the member be receiving radiation therapy?
    - Yes**
    - i. What is the patient's risk?  Intermediate  High  Very High
    - ii. How will the drug be given in relation to the radiation therapy?  Neoadjuvant  Concomitant  Adjuvant
  - No**
    - i. Please indicate if the member has any of the following (please indicate all that apply):
      - Disease recurrence after radiation therapy or brachytherapy
      - Very high risk disease and is not a candidate for definitive therapy
      - Progressive castration-naïve disease after radiation therapy, brachytherapy, or radical prostatectomy
- a) Is there any other information the physician's office can share about the member's disease state?  
\_\_\_\_\_

**Endometriosis**

- a) Have symptoms recurred after 6 months of therapy? **Yes or No**
- b) Will the member be concomitantly receiving Norethindrone? **Yes or No**
- c) How many total weeks of therapy has the member previously received of the requested drug?  
\_\_\_\_\_
- d) Does the member have pain? **Yes or No**
  - If **Yes**, what is the severity of the pain?  Mild  Moderate  Severe
- e) Does the member have Dyspareunia? **Yes or No**
- f) Does the member have moderate hepatic impairment (Child-Pugh Class B)? **Yes or No**

**Uterine Fibroids (Leiomyomata)**

- a) Has the member undergone Endometrial Ablation? **Yes or No**

**Precocious Puberty**

**Ovarian Cancer**

**Ovarian Protection during Chemotherapy**

- a) Will the member be receiving chemotherapy chemotherapy treatment? **Yes or No**
- b) Is the member premenopausal? **Yes or No**

**Breast Cancer**

- a) Is the breast cancer recurrent? **Yes or No**
- b) Is the breast cancer metastatic? **Yes or No**
- c) What is the member's menopausal status?  Premenopausal  Postmenopausal  Perimenopausal
- d) Does the member have hormone receptor positive breast cancer? **Yes or No**
- e) What therapies will this medication be given in combination with? \_\_\_\_\_  
\_\_\_\_\_

**Dysfunctional (Abnormal) Uterine Bleeding**

- a) Has the member undergone Endometrial Ablation? **Yes or No**

Physician office's signature\* \_\_\_\_\_ Print Name \_\_\_\_\_

\*Form must be completed and signed by physician or licensed representative from the physician's office.

Member Name: \_\_\_\_\_ Member ID: \_\_\_\_\_ Member DOB: \_\_\_\_\_

Drug Name: \_\_\_\_\_ Strength: \_\_\_\_\_ Directions (including frequency): \_\_\_\_\_

Physician Name: \_\_\_\_\_ Physician Phone #: \_\_\_\_\_ Specialty: \_\_\_\_\_

Physician Fax #: \_\_\_\_\_ Pharmacy Name: \_\_\_\_\_ Pharmacy Phone: \_\_\_\_\_

**Menorrhagia (Heavy bleeding)/ Excessive or frequent menstruation (ICD-9 code 626.2)**

- a) What is the heavy bleeding associated with? (If it is due to one of the listed diagnoses, please also choose that diagnosis and answer related questions).
- \_\_\_\_\_

**Suppression of Menstruation or Ovarian Protection after Transplant**

- a) Is the member post-Bone Marrow Transplant? **Yes or No**  
b) Is the member premenopausal? **Yes or No**

**Gender Identity Disorder/Gender Incongruence or Gender Dysphoria**

**For Adolescent Members:**

- a) Is the member 10-19 years of age? **Yes or No**  
b) Has the member undergone surgery for gender reassignment (e.g. gonadectomy)? **Yes or No**  
c) Does the member suffer from a psychiatric comorbidity that interferes with the diagnostic work-up or treatment? **Yes or No**  
d) Will the member be psychological and social support during treatment? **Yes or No**

**For Adult Members:**

- a) Is the member 20 years of age or older? **Yes or No**  
b) Is the member receiving gender-affirming hormone therapy (e.g., testosterone, estrogen) together with GnRH **Yes or No**  
c) Has the member undergone surgery for gender reassignment (e.g. gonadectomy)? **Yes or No**

**Other:** \_\_\_\_\_

Physician office's signature\* \_\_\_\_\_ Print Name \_\_\_\_\_

\*Form must be completed and signed by physician or licensed representative from the physician's office.